David D. Hurd - Concepedia

Author

David D. Hurd

Wake Forest University

Also Known As

Baxter-Lowe, Lee Ann, D D Hurd, D HURD, D Hurd, D. D. Hurd, D. HURD, D. Hurd, D.D. Hurd, David D Hurd, David D. Hurd

237

Publications

10.2K

Citations

H-Index

117

Concepts

All Affiliations

Wake Forest University University of Minnesota The Ohio State University Dana-Farber Cancer Institute Washington University in St. Louis

About

David D. Hurd is an author at Wake Forest University specializing in medicine, hematology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	26	47	2.1K
2	Health Sciences	15	20	1.1K
3	Arts	1	1	23
4	Nursing	1	1	23
5	Public Health	1	1	18

David D. Hurd

108

Publications

9.9K

Citations

H-Index

Page 1

	Year	Citations
Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741 Marc L. Citron, Donald A. Berry, Constance Cirrincione, Journal of Clinical Oncology	2003	1.6K
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma Philip L. McCarthy, Kouros Owzar, Craig C. Hofmeister, New England Journal of Medicine	2012	1.1K
Chemotherapy Compared with Autologous or Allogeneic Bone Marrow Transplantation in the Management of Acute Myeloid Leukemia in First Remission Peter A. Cassileth, David P. Harrington, Frederick R. Appelbaum, New England Journal of Medicine	1998	609
Standard Chemotherapy Compared With High-Dose Chemoradiotherapy for Multiple Myeloma: Final Results of Phase III US Intergroup Trial S9321 Bart Barlogie, Robert A. Kyle, Kenneth C. Anderson, Journal of Clinical Oncology	2006	495
Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma Paul G. Richardson, Susanna Jacobus, Edie Weller, New England Journal of Medicine	2022	428
Comparison of Autologous and Allogeneic Bone Marrow Transplantation for Treatment of High-Risk Refractory Acute Lymphoblastic Leukemia John H. Kersey, Daniel Weisdorf, Mark E. Nesbit, New England Journal of Medicine	1987	330
Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide Peter Westervelt, Randy A. Brown, Douglas R. Adkins, Blood	2001	247
Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. James Gajewski, G. L. Phillips, K. A. Sobocinski, Journal of Clinical Oncology	1996	198
A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma Todd A. Fehniger, Sarah M. Larson, Kathryn Trinkaus, Blood	2011	192
Immunochemotherapy and Autologous Stem-Cell Transplantation for Untreated Patients With Mantle-Cell Lymphoma: CALGB 59909 Lloyd E. Damon, Jeffrey L. Johnson, Donna Niedzwiecki, Journal of Clinical Oncology Mantle-cell LymphomaCell TherapyImmunologyPathologyImmunotherapeutics	2009	188

Page 1